Key result
Prior antiplatelet therapy did not prevent cerebral and myocardial infarction, nor did it increase the risk of major bleeding in patients with infective endocarditis.
Why the study?
Does prior antiplatelet therapy prevent major adverse cardiac events in patients diagnosed with infective endocarditis?
Cohort
Does prior antiplatelet therapy prevent major adverse cardiac events in patients diagnosed with infective endocarditis?
Prior antiplatelet therapy does not appear to prevent ischemic stroke or myocardial infarction, nor does it increase major bleeding risk in patients with infective endocarditis.
Answers are grounded in this paper and cite their sources.
Prior antiplatelet therapy was not associated with fewer ischemic events in infective endocarditis; leaves open whether randomized trials are warranted.
Background: Infective endocarditis (IE) occurs with an incidence of about 3–10 per 100,000 person-years globally. Those with infective endocarditis complicated embolic events have worse outcomes. However, whether antiplatelet therapy could prevent the development of ischemic stroke and myocardial infarction remained unknown. Materials and Methods: We conducted a retrospective cohort study using Taiwan National Health Insurance Research Database to access the effect of prior antiplatelet therapy on major adverse cardiac events in patients diagnosed with infective endocarditis. Results: The clinical characteristics and the risk of subsequent major adverse cardiac events in 901 patients with infective endocarditis with prior antiplatelet therapy and a matched cohort without antiplatelet therapy were retrospectively analyzed. The majority (63%) of the patients with prior antiplatelet therapy were male and 568 (57.7%) had a high (≥3) Charlson Cormorbidity Index score. There was no significant difference in the risk of myocardial infarction, ischemic stroke, and major bleeding between the two groups. The tests of interaction showed the risk of myocardial infarction was contingent on heart failure. Conclusions: Prior antiplatelet therapy did not prevent the cerebral and myocardial infarction in those with infective endocarditis. Neither did them increase the risk of major bleeding in patients with infective endocarditis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) conducted a cohort in Infective endocarditis. Prior antiplatelet therapy vs. No prior antiplatelet therapy was evaluated on Major adverse cardiac events (myocardial infarction, ischemic stroke, and major bleeding). Prior antiplatelet therapy did not prevent cerebral and myocardial infarction, nor did it increase the risk of major bleeding in patients with infective endocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: